29 Jun 2022 Avacta announces second dose escalation in the Phase I clinical study of AVA6000 Pro-doxorubicin Investors | Therapeutics
16 May 2022 AffyXell expands its strategic partnership with GenScript ProBio Investors | Therapeutics
11 May 2022 Avacta establishes new Therapeutics headquarters at Scale Space, Imperial College White City Campus Investors | Therapeutics
12 Apr 2022 Poster presented at the American Association for Cancer Research Annual Meeting available to download Investors | Therapeutics
08 Apr 2022 AffyXell partners with Biocytogen and the Korea Non-clinical Technology Support Center Investors | Therapeutics
29 Mar 2022 Avacta to present pre-clinical data on AVA6000 at the American Association for Cancer Research Annual Meeting Investors | Therapeutics